UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PP 17 Monitoring phosphorylation of p70S6K1 kinase (Thr421/Ser424), a biological marker for mTOR activity, improves Nottingham histoprognostic grading of invasive breast carcinomas

European journal of cancer (1990), 2011, Vol.47, p.S29-S29

2011

Volltextzugriff (PDF)

487P HER2DX ERBB2 mRNA assay following trastuzumab-based chemotherapy in HER2-positive (HER2+) advanced gastric cancer (AGC)

Annals of oncology, 2024-06, Vol.35, p.S194-S194

2024

Volltextzugriff (PDF)

469P 16-year outcomes of radically treated localized gastric cancer (GC) patients (pt): Real-world data (RWD) of a Spanish institution

Annals of oncology, 2024-06, Vol.35, p.S188-S188

2024

Volltextzugriff (PDF)

367P Chemotherapy sensitivity in pancreatic neoplasms with PALB2 Gene mutations: First results of PALB2 pancreatic cancer study

Annals of oncology, 2024-06, Vol.35, p.S149-S150

2024

Volltextzugriff (PDF)

352P Mutations of SMAD4 and FBXW7 predict poor outcome in TP53-driven metastatic colorectal cancer

Annals of oncology, 2022-09, Vol.33, p.S697

2022

Volltextzugriff (PDF)

1636P Circulating tumor DNA (ctDNA) profile in patients (pts) with pancreatic cancer (PC): A multicenter experience and challenges for clinical application

Annals of oncology, 2023-10, Vol.34, p.S905-S905

2023

Volltextzugriff (PDF)

125P Assessing the accuracy of multiple prognostic scores for immune checkpoint inhibitors (ICI) in patients with advanced solid tumors

Annals of oncology, 2022-09, Vol.33, p.S594-S595

2022

Volltextzugriff (PDF)

2P Lung immune prognostic index (LIPI) can identify the fast-progressor to immune checkpoints inhibitors (ICI) in microsatellite instability (MSI) or mismatch repair deficient (dMMR) tumours

Annals of oncology, 2020-12, Vol.31, p.S1418-S1418

2020

Volltextzugriff (PDF)

Different RNA expression profile defines prognosis in grade 1/2 neuroendocrine neoplasms of small intestine origin: The GETNE-NETSEQ study

Annals of oncology, 2017-09, Vol.28, p.v143-v143

2017

Volltextzugriff (PDF)

700PA PHASE (PH) I/II TRIAL TO EVALUATE THE EFFICACY (E) AND SAFETY (S) OF NAB-PACLITAXEL (NAB-P) IN COMBINATION (CO) WITH GEMCITABINE (G) FOR THE TREATMENT (TR) OF FRAIL (FR) PATIENTS (P) WITH ADVANCED OR METASTATIC PANCREATIC CANCER (APC): SAFETY RESULTS OF THE PHASE I TRIAL

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv238-iv238

2014

Volltextzugriff (PDF)

A Phase (Ph) I/II Trial to Evaluate the Efficacy (E) and Safety (S) of Nab-Paclitaxel (Nab-P) in Combination (Co) with Gemcitabine (G) for the Treatment (Tr) of Frail (Fr) Patients (P) with Advanced or Metastatic Pancreatic Cancer (Apc): Safety Results of the Phase I Trial

Annals of oncology, 2014-09, Vol.25, p.iv238

2014

Volltextzugriff (PDF)

P1-12-14: Genetic Ablation or Pharmacological Inhibition of Autophagy Suppresses Intrinsic Resistance of Breast Cancer to HER2−Targeted Therapies

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P1-P1-12-14

2011

Volltextzugriff (PDF)

P4-09-23: Monitoring Autophosphorylation of Mammalian Target of Rapamycin (mTOR) for Histoprognostic Grading of Invasive Breast Cancer: Impact on the Reclassification of Patients with Grade 2 Tumors Using the Nottingham Grading System

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P4-P4-09-23

2011

Volltextzugriff (PDF)

Development and characterization of an experimental model of diet-induced metabolic syndrome in rabbit

PloS one, 2017-05, Vol.12 (5), p.e0178315-e0178315

2017

Volltextzugriff (PDF)

Experiences of water poverty in the metropolitan area of Barcelona: implications for the Global North

Journal of water, sanitation, and hygiene for development, 2024-09, Vol.14 (9), p.819-832

2024

Volltextzugriff (PDF)

Ser2481-autophosphorylated mTOR colocalizes with chromosomal passenger proteins during mammalian cell cytokinesis

Cell cycle (Georgetown, Tex.), 2012-11, Vol.11 (22), p.4211-4221

2012

Volltextzugriff (PDF)

Insights into the Use of Peripherally Acting μ-Opioid Receptor Antagonists (PAMORAs) in Oncologic Patients: from Scientific Evidence to Real Clinical Practice

Current treatment options in oncology, 2021-03, Vol.22 (3), p.26-26, Article 26

2021

Volltextzugriff (PDF)

Abstract C005: Exploratory biomarker evaluation of the randomized Phase 2 cohort of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer

Cancer research (Chicago, Ill.), 2024-09, Vol.84 (17_Supplement_2), p.C005-C005

2024

Volltextzugriff (PDF)

Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies

Biochemical and biophysical research communications, 2011-04, Vol.407 (2), p.412-419

2011

Volltextzugriff (PDF)

New Targets and New Drug Development in Colorectal Cancer

Current colorectal cancer reports, 2014-09, Vol.10 (3), p.288-295

2014

Volltextzugriff (PDF)

Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib

Breast cancer research : BCR, 2011-01, Vol.13 (1), p.401-401, Article 401

2011

Volltextzugriff (PDF)

Els arxius de les administracions locals

Revista de Girona, 1999 (197)

1999

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(21)
magazinearticle
(1)

Sprache

Englisch
(21)
Katalanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(7)
Life Sciences & Biomedicine
(5)
Humans
(4)
Oncology
(3)
Antineoplastic Agents - Pharmacology
(2)
Cancer
(2)
Fatty Acids
(2)
Female
(2)
Medicine
(2)
Medicine & Public Health
(2)
Proteins
(2)
Section Editor
(2)
Tyrosine
(2)
4-Butyrolactone - Analogs & Derivatives
(1)
60 Applied Life Sciences
(1)
Abdomen
(1)
Age Factors
(1)
Analysis
(1)
Analysis Of Variance
(1)
Animal Models
(1)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

PP 17 Monitoring phosphorylation of p70S6K1 kinase (Thr421/Ser424), a biological marker for mTOR activity, improves Nottingham histoprognostic grading of invasive breast carcinomas

487P HER2DX ERBB2 mRNA assay following trastuzumab-based chemotherapy in HER2-positive (HER2+) advanced gastric cancer (AGC)

469P 16-year outcomes of radically treated localized gastric cancer (GC) patients (pt): Real-world data (RWD) of a Spanish institution

367P Chemotherapy sensitivity in pancreatic neoplasms with PALB2 Gene mutations: First results of PALB2 pancreatic cancer study

352P Mutations of SMAD4 and FBXW7 predict poor outcome in TP53-driven metastatic colorectal cancer

1636P Circulating tumor DNA (ctDNA) profile in patients (pts) with pancreatic cancer (PC): A multicenter experience and challenges for clinical application

125P Assessing the accuracy of multiple prognostic scores for immune checkpoint inhibitors (ICI) in patients with advanced solid tumors

2P Lung immune prognostic index (LIPI) can identify the fast-progressor to immune checkpoints inhibitors (ICI) in microsatellite instability (MSI) or mismatch repair deficient (dMMR) tumours

Different RNA expression profile defines prognosis in grade 1/2 neuroendocrine neoplasms of small intestine origin: The GETNE-NETSEQ study

700PA PHASE (PH) I/II TRIAL TO EVALUATE THE EFFICACY (E) AND SAFETY (S) OF NAB-PACLITAXEL (NAB-P) IN COMBINATION (CO) WITH GEMCITABINE (G) FOR THE TREATMENT (TR) OF FRAIL (FR) PATIENTS (P) WITH ADVANCED OR METASTATIC PANCREATIC CANCER (APC): SAFETY RESULTS OF THE PHASE I TRIAL

A Phase (Ph) I/II Trial to Evaluate the Efficacy (E) and Safety (S) of Nab-Paclitaxel (Nab-P) in Combination (Co) with Gemcitabine (G) for the Treatment (Tr) of Frail (Fr) Patients (P) with Advanced or Metastatic Pancreatic Cancer (Apc): Safety Results of the Phase I Trial

P1-12-14: Genetic Ablation or Pharmacological Inhibition of Autophagy Suppresses Intrinsic Resistance of Breast Cancer to HER2−Targeted Therapies

P4-09-23: Monitoring Autophosphorylation of Mammalian Target of Rapamycin (mTOR) for Histoprognostic Grading of Invasive Breast Cancer: Impact on the Reclassification of Patients with Grade 2 Tumors Using the Nottingham Grading System

Development and characterization of an experimental model of diet-induced metabolic syndrome in rabbit

Experiences of water poverty in the metropolitan area of Barcelona: implications for the Global North

Ser2481-autophosphorylated mTOR colocalizes with chromosomal passenger proteins during mammalian cell cytokinesis

Insights into the Use of Peripherally Acting μ-Opioid Receptor Antagonists (PAMORAs) in Oncologic Patients: from Scientific Evidence to Real Clinical Practice

Abstract C005: Exploratory biomarker evaluation of the randomized Phase 2 cohort of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer

Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies

New Targets and New Drug Development in Colorectal Cancer

Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib

Els arxius de les administracions locals

Suchergebnisse filtern